Skip to main content

Month: August 2022

W&T Offshore Announces Strong Second Quarter 2022 Results

Net Income Totaled $123.4 Million, or $0.85 per Share HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”) today reported operational and financial results for the second quarter 2022. This press release includes non-GAAP financial measures, including Adjusted Net Income, Adjusted EBITDA, Free Cash Flow, and Net Debt, which are described and reconciled to the most comparable GAAP measures below in the accompanying tables under “Non-GAAP Information.” Key highlights for the second quarter 2022 and through the date of this press release included:Increased production by 12% quarter-over-quarter to 42.4 thousand barrels of oil equivalent per day (“MBoe/d”) (48% liquids), or 3.9 million barrels of oil equivalent (“MMBoe”), exceeding the high end of previously disclosed quarterly...

Continue reading

uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Huntingtin protein (mHTT) observed in cerebral spinal fluid (CSF) ~ ~ Announced postponement of AMT-130 higher-dose procedures due to recent suspected unexpected severe adverse reactions at this dose; Lower-dose procedures are not affected and no impact is expected on anticipated data readouts in 2023 ~ ~ Advancing regulatory reviews of the U.S. and European marketing applications for etranacogene dezaparvovec in hemophilia B ~ ~ Investor conference call and webcast today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Aug. 08, 2022 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...

Continue reading

Kandi Technologies Reports Second Quarter 2022 Financial Results

–  Off-road Vehicles Sales Are Steadily Growing–  Quarter-end cash balance1 increased to $232.5 million JINHUA, China, Aug. 08, 2022 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (the “Company,” “we” or “Kandi”) (NASDAQ GS: KNDI), today announced its financial results for the second quarter of 2022. Second Quarter HighlightsTotal revenues of $20.8 million compared to $29.9 million in the same period of 2021.Off-road vehicles sales increased by 84.4% to $10.1 million, compared to $5.5 million in the same period of 2021.EV products sales increased by 307.1% to $2.5 million, compared to $0.6 million in the same period of 2021.EV parts sales were $0.6 million, compared to $6.7 million in the same period of 2021.Electric Scooters, Electric Self-Balancing Scooters and associated parts sales were $1.2 million,...

Continue reading

Tyson Foods Reports Third Quarter 2022 Results

Company Focused on Aggressively Managing Costs and More Efficient Operations, Continued Improvement in Chicken Segment SPRINGDALE, Ark., Aug. 08, 2022 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, today reported the following results:(in millions, except per share data) Third Quarter   Nine Months Ended  2022   2021   2022   2021Sales $ 13,495   $ 12,478   $ 39,545   $ 34,238Operating Income   1,033     1,062     3,644     2,487               Net Income   753     753     2,712     1,702Less: Net Income Attributable to Noncontrolling Interests   3     4     12     10Net Income Attributable to Tyson $ 750   $ 749   $ 2,700   $ 1,692               Net...

Continue reading

Luckin Coffee Inc. Announces Second Quarter 2022 Financial Results

Second Quarter Net Revenues Increased 72%; 615 Net New Store Openings Continued Improvement in Profitability ProfileSustainable Development Committee Formed to Advise on ESG Initiatives, Policies and Disclosures BEIJING, Aug. 08, 2022 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced its unaudited financial results for the three months ended June 30, 2022. SECOND QUARTER 2022 HIGHLIGHTS1Total net revenues in the second quarter were RMB3,298.7 million (US$493.2 million), representing an increase of 72.4% from RMB1,913.7 million in the same quarter of 2021.Net new store openings in the second quarter was 615, resulting in a quarter-over-quarter store unit growth of 9.3% from the number of stores at the end of the first quarter of 2022, ending the second quarter with 7,195 stores...

Continue reading

Prairie Provident Resources Announces Strong Second Quarter 2022 Financial and Operating Results

CALGARY, Alberta, Aug. 08, 2022 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident”, “PPR” or the “Company”) today announces our financial and operating results for the three and six months ended June 30, 2022. PPR’s unaudited condensed interim consolidated financial statements for the three and six months ended June 30, 2022 and related Management’s Discussion and Analysis (“MD&A”) for the same periods are available on our website at www.ppr.ca and filed on SEDAR. MESSAGE TO SHAREHOLDERS Tony Berthelet, President & Chief Executive Officer commented: “Q2 saw the continued growth in operating netback1 again highlighting the cash generating potential of our low decline base production. We continue to unlock the Banff potential in Michichi through waterflood expansion,...

Continue reading

Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S. has Declared Monkeypox a Public Health Emergency U.S. National Institute of Drug Abuse (NIDA) Grant Awarded for the Development of TNX-1300 for Cocaine Intoxication; Phase 2 Study of TNX-1300 Expected to Initiate in Fourth Quarter 2022 Advanced Development Center in Dartmouth, Mass. is Open and Expected to Imminently Conduct Process Development and Clinical Trial Manufacturing of Live-Virus Vaccines Cash and Cash Equivalents Totaled Approximately $145 Million at June 30, 2022 CHATHAM, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results...

Continue reading

PowerFleet Reports 10-Quarter Revenue High and Improved Bottom Line Performance for Second Quarter 2022

Quarterly Revenue of $34.6 Million, Marking Third Consecutive Quarter of Year-Over-Year Revenue Growth High Margin, Recurring and Services Revenue up 9% Year-Over-Year to $19.8 Million, Reflecting Company’s Focus on Driving SaaS and Software Revenue Rationalization Initiatives Drive 58% Sequential Improvement in Loss from Operations Strong First Half 2022 Financial Results, Position Company for Growth, and Improved Profitability for Full Year 2022WOODCLIFF LAKE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — PowerFleet, Inc. (Nasdaq: PWFL), a global leader of Internet-of-Things (IoT) solutions that manage enterprise assets for seamless business operations, reported results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial HighlightsTotal revenue was $34.6 million, an increase of 4% quarter-over-quarter. High...

Continue reading

Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update

– Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia – – Received U.S. FDA orphan drug designation for VGL101 for the treatment of patients with ALSP – – Prioritizing VGL101 in ALSP and small molecule TREM2 agonist programs; cash runway now extended through the end of the second quarter of 2024 – – On track to report top line data from the VGL101 Phase 1 trial in healthy volunteers and initiate the Phase 2 trial in ALSP patients in the fourth quarter of 2022 – – Further strengthened Board of Directors with appointment of Suzanne Bruhn, Ph.D. – CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the...

Continue reading

Assertio Reports Second Quarter 2022 Financial Results

Net Product Sales Increase 40% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases to $22.9 million Raises Full Year Revenue and Non-GAAP Adjusted EBITDA Guidance LAKE FOREST, Ill., Aug. 08, 2022 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the second quarter ended June 30, 2022. Financial Highlights (unaudited):  Three Months Ended June 30,   Six Months Ended June 30,(in millions, except per share amounts)   2022     2021       2022     2021  Net Product Sales (GAAP) $         35.4   $         25.2     $         71.0   $         51.3  Net Income (loss) (GAAP) $ 7.8   $         (14.2 )   $ 16.9   $         (9.6 )Earnings (loss) Per Share (GAAP) $ 0.16   $         (0.32 )   $ 0.36   $         (0.23 )Adjusted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.